Table 1 Demographic characteristics. Percentage relative to the total at the top row is presented in brackets. Chi-square contingency analysis was performed where indicated. Statistically significant results are highlighted in italic and an asterisk

Total N

93

578

81

402

69

241

Sex, n (%)

0.218

 Male

48 (51.6)

246 (42.6)

43 (53.1)

174 (43.3)

37 (53.6)

107 (44.4)

 Female

45 (48.4)

332 (57.4)

38 (46.9)

228 (56.7)

32 (46.4)

134 (55.6)

Age, Avg [Min-Max]

65 [39–81]

66 [37–88]

65 [39–80]

66 [37–88]

65 [39–80]

65 [41–87]

0.812

PS, n (%)

0.192

 PS0

14 (15.1)

64 (11.1)

14 (17.3)

45 (11.2)

14 (20.3)

29 (12)

 PS1

41 (44.1)

288 (49.8)

33 (40.7)

189 (47)

26 (37.7)

122 (50.6)

 PS2

34 (36.6)

205 (35.5)

30 (37)

149 (37.1)

25 (36.2)

83 (34.4)

 PS3

3 (3.2)

20 (3.5)

3 (3.7)

18 (4.5)

3 (4.3)

6 (2.5)

 PS4

1 (1.1%)

1 (0.2%)

1 (1.2%)

1 (0.2%)

1 (1.4%)

1 (0.4%)

Comorbidities, n (%)

0.140

 None

26 (28)

85 (14.7)

21 (25.9)

60 (14.9)

17 (24.6)

37 (15.4)

 Mild

40 (43)

320 (55.4)

35 (43.2)

222 (55.2)

33 (47.8)

134 (55.6)

 Moderate

24 (25.8)

162 (28)

23 (28.4)

111 (27.6)

17 (24.6)

66 (27.4)

 Severe

3 (3.3)

11 (1.9)

2 (2.4)

9 (2.2)

2 (2.8)

4 (1.7)

Stage, n (%)

 Stage I

1 (1.1)

11 (1.9)

–

–

–

–

–

 Stage II-III

23 (24.7)

326 (56.4)

12 (14.8)

161 (40)

–

–

 Stage IV

69 (74.2)

241 (41.7)

69 (85.2)

241 (60)

69 (100)

241 (100)

Disease extent, n (%)

 Limited

12 (12.9)

176 (30.4)

–

–

–

–

 Extensive

81 (87.1)

402 (69.6)

81 (100)

402 (100)

69 (100)

241 (100)

SVCO at presentation

4 (4.3)

36 (6.2)

4 (4.9)

30 (7.5)

2 (2.9)

14 (5.8)

0.538